Metformin Medreg

Metformin, the active ingredient in Metformin Medreg, is a Biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control.

GNH USA supplies Metformin Medreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for conditions related to abnormal glucose metabolism and insulin resistance.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Impaired glucose tolerance: helps delay progression to overt diabetes. Metabolic syndrome: improves insulin sensitivity and may aid weight management.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea or vomiting - Diarrhoea - Abdominal discomfort or flatulence - Metallic taste in the mouth - Decreased appetite - Mild weight loss

Serious or Rare Side Effects: - Lactic acidosis (rare but potentially fatal) - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction - Vitamin B12 deficiency with long‑term use - Hypoglycaemia when combined with other antidiabetic agents

Metformin requires careful monitoring in several clinical situations. - Renal function: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic disease: use with caution; monitor liver enzymes. - Risk of lactic acidosis: discontinue before radiographic contrast studies. - Alcohol consumption: limit intake to reduce acidosis risk. - Pregnancy and lactation: assess risk‑benefit; data are limited. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Metformin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis. - Loop diuretics causing dehydration. - Other antidiabetic agents that may cause hypoglycaemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function. - Warfarin: occasional changes in INR. - Oral contraceptives: may affect glucose control. - Digoxin: monitor for altered levels.